Peter Altman

This profile gathers the share dealings of Peter Altman in BioCardia, Inc., where the filings describe the role as chief executive. Between 10 June 2021 and 29 September 2026, the trades on record add up to 83 filings.

Purchases make up the whole of the open-market record (67 purchases, €322k). The amount is not disclosed for 3 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 16 share grants. Since January 2026: 25 purchases and no sales on the market.

The median purchase comes to €1,497. Relative to company size, the median is 0.011% of market cap (19 purchases with a known value). Clusters matter here: 8 out of 64 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster. For 40 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 35% of cases, with a median move of -12.4%. This is a record of the past, not a forecast.

The newest entry dates from 30 September 2026: an open-market purchase of €906, in BioCardia, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.